Expert Insights

Stefania Napolitano, MD, PhD, discusses results from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.

Stefania Napolitano, MD, PhD, discusses background and methods from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.

Eric Mastrolonardo, MD, discusses findings from a systematic review and meta-analysis evaluating whether pathologic treatment response after neoadjuvant immune checkpoint inhibition is associated with survival outcomes in resectable mucosal...

Stephen Lam Chan, MD, discusses results from the phase 3 KEYNOTE-937 trial which demonstrated that adjuvant pembrolizumab did not significantly improve recurrence-free survival following curative-intent resection or local ablation for...

Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.

Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.

Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...

Jessica Walchonski, PA-C, MMS, reviewed recent advances in gynecologic oncology, highlighting new targeted and immunotherapy options for ovarian cancer and evolving strategies for endometrial cancer at the 2025 Oncology Learning Network APP...

Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.

Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.